ArticleOncotarget2010
An activating transcription factor 5-mediated survival pathway as a target for cancer therapy?
Article in Oncotarget, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Multilayered control of mRNA delivery to cell protrusions drives localized mini-cytoplasm establishment for stress-induced cell activation.Nature communications · 2026Article
- Stiff extracellular matrix activates the transcription factor ATF5 to promote the proliferation of cancer cells.iScience · 2025Article
- Activating Transcription Factor 5 Promotes Neuroblastoma Metastasis by Inducing Anoikis Resistance.Cancer research communications · 2023Article
- TTYH3 Modulates Bladder Cancer Proliferation and Metastasis via FGFR1/H-Ras/A-Raf/MEK/ERK Pathway.International journal of molecular sciences · 2022Article
- Systems Biomedicine of Primary and Metastatic Colorectal Cancer Reveals Potential Therapeutic Targets.Frontiers in oncology · 2021Article
- Dominant-negative ATF5 rapidly depletes survivin in tumor cells.Cell death & disease · 2019Article
- Expression of activating transcription factor 5 (ATF5) is increased in astrocytomas of different WHO grades and correlates with survival of glioblastoma patients.OncoTargets and therapy · 2018Article
- Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis.Nature communications · 2017Article
- Human cytomegalovirus immediate-early protein promotes survival of glioma cells through interacting and acetylating ATF5.Oncotarget · 2017Article
- A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Regression/eradication of gliomas in mice by a systemically-deliverable ATF5 dominant-negative peptide.Oncotarget · 2016Article
- Differential expression of two activating transcription factor 5 isoforms in papillary thyroid carcinoma.OncoTargets and therapy · 2016Article
- Potential Role of Activating Transcription Factor 5 during Osteogenesis.Stem cells international · 2016Article
- Association between human cytomegalovirus infection and histone acetylation level in various histological types of glioma.Oncology letters · 2015Article
- DNA methylation level of promoter region of activating transcription factor 5 in glioma.Journal of Zhejiang University. Science. B · 2015Article
- Phospho-ΔNp63α/microRNA feedback regulation in squamous carcinoma cells upon cisplatin exposure.Cell cycle (Georgetown, Tex.) · 2013Article
- Recent progress in targeting cancer.Aging · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Genes that are highly expressed in cancer cells and are essential for their viability are attractive targets for the development of novel cancer therapeutics. Activating transcription factor 5 (ATF5) is an anti-apoptotic protein that is highly expressed in malignant glioma but not normal brain tissues, and is essential for glioma cell survival. Recent work has revealed an essential survival pathway mediated by ATF5 in malignant glioma; pharmacological inhibition of this pathway leads to tumor regression in mice. ATF5 is also highly expressed in a variety of other cancers, and preliminary studies have shown that the ATF5-mediated survival pathway is active in diverse human cancer cell lines. Targeting this pathway may therefore have therapeutic implications for the treatment of a wide range of cancers. In this perspective, we summarize recent advances in ATF5 research, focusing on its role in promoting cancer and its potential as a target for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.